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LDL-C = low-density
lipoprotein cholesterol
sCr = serum creatinine
STEMI = ST-segment
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infarction
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63higher in patients with conditions such as diabetes mellitus
(DM) or chronic kidney disease (CKD) (2,3). Therefore,
strategies to prevent CI-AKI in DM patients with CKD are
urgently needed.
CI-AKI mechanisms are complex but may be related to
direct renal tubular toxicity, vasoconstriction, and high oxi-
dative stress. Statins have beneﬁcial effects on endothelial
function, nitric oxide production, and oxidative stress, which
are directly related to the development of CI-AKI (4,5).
Statins have renoprotective effects in patients with CKD
(6,7). However, results for the efﬁcacy of statin therapy to
prevent CI-AKI in high-risk patients are inconsistent,
mostly because of small sample sizes (8–15). Despite this,
the latest European Society of Cardiology guidelines on
myocardial revascularization advise the use of statins to
prevent CI-AKI, especially in high-risk patients (16).
The purpose of this clinical trial was to examine the
effects of short-term rosuvastatin therapy on the incidence of
CI-AKI in a multicenter, prospective trial in patients with
DM and with mild-to-moderate CKD undergoing coro-
nary/peripheral arterial diagnostic angiography, left ven-
triculography, or percutaneous coronary intervention (PCI).Methods
Study population. This study was an investigator-initiated,
prospective, randomized, controlled, multicenter clinical trial
performed in China, designed by the steering committee
and registered at Clinicaltrials.gov (NCT00786136).
Patients with DM and CKD undergoing coronary/periph-
eral arterial diagnostic angiography, left ventriculography, or
PCI were eligible.
The primary objective was to evaluate the safety and
efﬁcacy of statin therapy for prevention of CI-AKI in
patients with DM and CKD exposed to contrast medium.
The trial included patients 18 to 75 years of age with type 2
DM and concomitant stage 2 or 3 CKD who had not
received any statin treatment for at least 14 days and in
whom metformin or aminophylline had been withdrawn for
at least 2 days prior to contrast medium administration
(Fig. 1). Exclusion criteria were hypersensitivity to contrast
medium or statins, type 1 DM, ketoacidosis, lactic acidosis,
stage 0 or 1 CKD, stage 4 or 5 CKD, acute ST-segment
elevation myocardial infarction (STEMI) within the
previous 4 weeks, class IV heart failure as deﬁned by the
New York Heart Association (NYHA) functional classiﬁca-
tion system, hemodynamic instability, administration of
iodinated contrast medium during the 2 weeks before
randomization, low-density lipoprotein cholesterol (LDL-C)
concentration <1.82 mmol/liter, hepatic dysfunction (serum
alanine-aminotransferase [ALT] concentration 3 times
greater than the upper limit of normal), thyroid insufﬁciency,
or renal artery stenosis (unilateral>70% or bilateral >50%).
The estimated glomerular ﬁltration rate (eGFR) was
calculated from serum creatinine (sCr) concentrations by using
the modiﬁed glomerular ﬁltration rate estimating equationfor Chinese patients with CKD
(17): eGFR (ml/min/1.73 m2) ¼
175  (sCr)1.234  (age)0.179
(0.79 if female).
Study protocol. The study was
approved by theEthicsCommittee
of Shenyang Northern Hospital.
All patients provided written
informed consent before enroll-
ment. Block randomization was
performed using computerized
open-label assignment by blinded
envelopes, used in a consecutive
fashion, with a block size of 6.
Patients were randomized to
receive either rosuvastatin (Crestor,
AstraZeneca, London, United
Kingdom), 10 mg every evening,
from 2 days before to 3 days after
contrast medium administration (total dose of 50 mg of rosu-
vastatin over 5 days) or to a control group. Patients assigned to
the control group did not receive any statins. Statin therapy was
resumed in both groups 3 days after contrast medium admin-
istration, following completion of the study endpoints.
Hydration therapy was standard and administered at the
physician’s discretion and included isotonic saline (0.9%
sodium chloride, 1 ml/kg/h) started 12 h before and
continued for 24 h after contrast medium administration.
The iso-osmolar, nonionic contrast medium iodixanol
(320 mg iodine/ml, Visipaque, GE Healthcare, Piscataway,
New Jersey) was administered during all procedures.
Blood samples were taken to measure sCr concentrations
before randomization and at 48 h and 72 h after contrast
medium administration. The peak post-procedural sCr value
was used for the primary endpoint evaluation. Renal func-
tion was measured using eGFR in all patients. Type 2 DM
was diagnosed using the criteria of the American Diabetes
Association (18). Levels of high-sensitivity C-reactive
protein (hsCRP), total cholesterol (TC), and low-density
lipoprotein cholesterol (LDL-C) were also measured using
commercial kits on the day of admission and 3 days after the
procedure. Urinary albumin excretion was assessed by
measurement of urinary concentrations of albumin and
creatinine (albumin/creatinine ratio [ACR]) in urine
samples collected on the morning of the day before
randomization and 3 days after the procedure. Urinary
albumin concentrations were measured using the immuno-
turbidimetry method.
Endpoints and deﬁnitions. The primary endpoint was
the development of CI-AKI, deﬁned as an increase in sCr
concentration 0.5 mg/dl (44.2 mmol/l) or 25% above
baseline at 72 h after exposure to the contrast medium.
Clinical outcomes included events occurring within 30
days after contrast: 1) all-cause death; 2) dialysis or
hemoﬁltration due to symptoms or signs of uremic
syndrome or management of refractory hypervolemia,
Figure 1 Patient Flowchart
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64hyperkalemia, or acidosis (19); or 3) worsening heart
failure, deﬁned as a deteriorated NYHA functional class
(class change 1).
All patients had a follow-up evaluation at a clinic visit or via
telephone contact at 30 days. The China Cardiovascular
Research Foundation (CCRF), an independent clinical
research organization, was responsible for database manage-
ment, safety monitoring, and adverse event evaluation. All
adverse events were adjudicated by a blinded, independent
clinical events committee. The CCRF reviewed the data
periodically to identify any potential safety issues.
Statistical analysis. Sample size calculation was performed
by assuming a 10% incidence of the primary endpoint in the
control group and a 30% reduction in the treatment arm.
From these assumptions, 2,712 patients were required
(1,356 per group) from which to detect a 30% relative
reduction in the incidence of the primary endpoint in the
treatment arm with 80% power and a 2-sided signiﬁcance
level of 5%.
Statistical analysis was based on the modiﬁed intention-
to-treat populations and performed using SAS version
9.13 software (SAS Institute Inc., Cary, North Carolina).
Comparisons among normally distributed continuous vari-
ables, expressed as mean  SD, were performed using
Student t tests; non-normally distributed continuous vari-
ables, presented as medians and interquartile ranges, were
analyzed using Wilcoxon rank-sum tests. The chi-square or
Fisher exact test was used for categorical data, expressed as
percentages. Logistic regression analysis was used to calcu-
late odds ratios for the comparison of CI-AKI rates betweengroups. All p values were 2-tailed, and statistical signiﬁcance
was deﬁned by a p value 0.05. All statistical analyses were
performed by the CCRF.
Results
Between December 2008 and October 2011, 3,082
patients were enrolled at 53 centers in China. Eighty-four
patients did not undergo angiography and were excluded.
In total, 2,998 patients were included: 1,498 patients were
allocated to the rosuvastatin group and 1,500 to the control
group. Among all patients, 1,751 (58.4%) were statin-
naive, and 1,247 (41.6%) had not taken statins for at
least 14 days due to poor compliance or other reasons but
had previously used statins. Thirty-two patients (1.07%)
deviated from the protocol: in the rosuvastatin group, 11
patients did not receive statin therapy at all, and 5 did not
receive a statin after contrast medium administration; in
the control group, 16 patients received statin therapy
(1.1%).
Baseline clinical characteristics were well balanced
between groups (Table 1). Of the 2,998 patients, 85.9%
underwent diagnostic coronary angiography and left ven-
triculography (n ¼ 2,575), 13.5% diagnostic coronary/
peripheral angiography and left ventriculography (n ¼ 405),
0.6% peripheral angiography (n¼ 18), 53% PCI (n¼ 1,589),
and 1% percutaneous peripheral intervention (n ¼ 30)
(Table 2). There were no signiﬁcant differences between
maximum sCr levels and minimum eGFR values for all
patients, minimum eGFR values for patients with stage 2
Table 1 Baseline Patient Characteristics
Variable
Rosuvastatin Group
(n ¼ 1,498)
Control Group
(n ¼ 1,500) p Value
Age (yrs) 61.45  8.64 61.44  8.64 0.97
Weight (kg) 72.32  10.42 72.88  10.29 0.14
Height (cm) 168.33  7.81 168.52  7.64 0.52
Male 963 (64.3) 991 (66.1%) 0.31
Smoking 463 (30.9) 491 (32.7) 0.17
Family history of
coronary heart
disease
112 (7.5) 104 (6.9) 0.57
History of statin use 0.85
Statin-naive 878 (58.6) 873 (58.2)
Previous statin use 620 (41.4) 627 (41.8)
Anemia status* 0.59
No anemia 1,337 (91.3) 1,344 (91.9)
Anemia 127 (8.7) 118 (8.1)
Diabetes history 0.95
5 yrs 831 (55.5) 840 (56.0)
>5 yrs and <10 yrs 284 (18.9) 283 (18.9)
10 years 383 (25.6) 377 (25.1)
Hypertension 1,066 (71.3) 1090 (72.7) 0.39
Hypertriglyceridemia 139 (9.3) 117 (7.8) 0.15
TIA/stroke 188 (12.6) 208 (13.9) 0.28
Congestive heart failure 228 (15.2) 237 (15.8) 0.66
Peripheral vascular
disease
45 (3.0) 37 (2.5) 0.37
History of liver disease 34 (2.3) 24 (1.6) 0.18
Prior myocardial
infarction
322 (21.5) 296 (19.7) 0.24
Myocardial ischemia 0.09
None 227 (15.1) 267 (17.8)
Silent myocardial
ischemia
12 (0.8) 12 (0.8)
Stable angina 76 (5.1) 95 (6.3)
Unstable angina 1,071 (71.5) 1,005 (67.0)
NSTEMI 112 (7.5) 121 (8.1)
Continued in the next column
Table 1 Continued
Variable
Rosuvastatin Group
(n ¼ 1,498)
Control Group
(n ¼ 1,500) p Value
Medications
Aspirin 1,397 (93.3) 1,419 (94.6) 0.127
ACEI 981 (65.5) 947 (63.3) 0.20
ARB 363 (24.2) 353 (23.6) 0.67
Beta-blocker 1,224 (81.7) 1,201 (80.2) 0.30
Insulin 486 (32.4) 457 (30.5) 0.254
Diuretic 321 (21.4) 329 (22.0) 0.72
Calcium antagonist 624 (41.7) 614 (41.0) 0.70
Heparin 923 (61.6) 944 (63.0) 0.44
Digitalis 132 (8.8) 131 (8.7) 0.95
Vitamin C 25 (1.7) 29 (1.9) 0.59
Dopamine 23 (1.5) 22 (1.5) 0.88
Sodium bicarbonate 21 (1.4) 26 (1.7) 0.46
Hydration 673 (44.9) 642 (42.8) 0.25
LVEF, % 62.27  8.87 61.96  8.91 0.42
NYHA functional
classiﬁcation
0.54
I 1,152 (76.9) 1,149 (76.6)
II 302 (20.2) 318 (21.2)
III 44 (2.9) 33 (2.2)
Laboratory
determinations:
Total cholesterol
(mg/dl)
177.88  46.02 177.11  45.24 0.67
LDL-C (mg/dl) 98.61  31.71 97.45  30.55 0.35
Fasting glucose
(mg/dl)
134.07  51.18 132.81  49.37 0.48
BMI (kg/m2) 25.49  3.01 25.64  2.93 0.16
*Values are mean  SD or n (%). Deﬁnition of anemia ¼ hemoglobin concentration <120 g/l in
males or <110 g/l in females.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BMI ¼
body mass index; LDL-C ¼ low-density lipoprotein cholesterol; LVEF ¼ left ventricular ejection
fraction; NSTEMI ¼ non-ST segment elevation myocardial infarction; NYHA ¼ New York Heart
Association; TIA ¼ transient ischemic attack.
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65CKD, minimum eGFR values for patients with stage 3
CKD, and ACR after contrast medium administration in the
rosuvastatin and control groups.
The incidence of CI-AKI was lower in the rosuvastatin-
treated group (2.3% vs. 3.9%, p ¼ 0.01) (Fig. 2). In the
subgroup of patients with stage 2 CKD, the incidence of CI-
AKI was 1.5% in the rosuvastatin group compared with
3.3% in controls (p ¼ 0.01). On the basis of these results,
62.5 patients would need to be treated (NNT) with rosu-
vastatin for 5 days to prevent the occurrence of one case of
CI-AKI.
There were no signiﬁcant differences in all-cause deaths
(rosuvastatin vs. controls, 0.2% vs. 0.3%, respectively; p ¼
0.73) or dialysis/hemoﬁltration (0% vs. 0.1%, respectively;
p ¼ 0.50) (Table 3). The incidence of worsening heart
failure was signiﬁcantly decreased following rosuvastatin
treatment (2.6% vs. 4.3%, respectively; p ¼ 0.02).
Multivariable analysis (Table 4) revealed that rosuvastatin
and hemoglobin were independently associated with
a decreased risk of CI-AKI. Independent predictors ofCI-AKI included baseline acute coronary syndrome (ACS),
NYHA functional classiﬁcation, and a decreased eGFR
(<60 ml/min/1.73 m2). The beneﬁt of rosuvastatin therapy
was consistently effective among various subgroups (Fig. 3).
Both statin-naive and non-naive patients showed a similar
trend toward receiving beneﬁt from rosuvastatin against the
occurrence of CI-AKI (Table 5). An interaction test showed
that statin history had no effect on CI-AKI occurrence in
the present study (p ¼ 0.776).
There were no signiﬁcant differences between the 2 groups
at baseline in TC (177.88  46.02 mg/dl vs. 177.11  45.24
mg/dl, rosuvastatin vs. controls, respectively; p¼ 0.67),LDL-C
(98.61  31.71 mg/dl vs. 97.45  30.55 mg/dl, respectively;
p ¼ 0.35), and hsCRP levels (0.40 mg/l; interquartile
range: 0.20 to 1.10 vs. 0.40 mg/l, respectively; interquartile
range: 0.20 to 0.90; p ¼ 0.95). Follow-up TC (151.20 
37.90 mg/dl vs. 182.91  39.83 mg/dl, respectively; p <
0.01), LDL-C (81.59 25.91mg/dl vs. 100.16 24.75mg/
dl, respectively; p < 0.01), and hsCRP levels (0.40 mg/l;
interquartile range: 0.20 to 0.93 vs. 0.50 mg/l; interquartile
range: 0.20 to 1.10 mg/l, respectively; p ¼ 0.01) were
Table 2 Biochemical and Procedural Characteristics
Variable
Rosuvastatin Group
(n ¼ 1,498)
Control Group
(n ¼ 1,500) p Value
Peripheral vascular
angiography
219 (14.6) 205 (13.7) 0.45
Coronary diagnostic
angiography
0.17
Normal 148 (10.1) 142 (9.8)
Single-vessel disease 330 (22.5) 367 (25.4)
Multi-vessel disease 991 (67.4) 935 (64.8)
Percutaneous coronary
intervention
808 (53.9) 782 (52.1) 0.32
Percutaneous peripheral
intervention
15 (1.0) 16 (1.1) 0.86
Serum creatinine (mmol/l)
Baseline 95.08  22.92 94.95  20.84 0.88
Maximal post-procedural
value
95.12  25.39 95.71  29.01 0.55
eGFR (ml/min/1.73 m2)
All patients at baseline 74.16  14.99 74.43  15.24 0.62
Stage 2 CKD at baseline 78.46  11.37 78.99  11.27 0.24
Stage 3 CKD at baseline 50.20  8.90 49.56  8.70 0.43
Microalbuminuria (mg/dl)
Baseline 29.83  46.60 30.89  44.65 0.63
Post-procedural 24.18  39.38 25.60  42.32 0.47
ACR
Baseline 0.22  1.82 0.13  1.02 0.23
Post-procedural 0.18  1.36 0.15  1.06 0.68
Median contrast agent
dose, ml
120 (100–200) 110 (100–200) 0.10
Values are n (%), mean  SD, or median (interquartile range).
ACR ¼ urinary albumin/creatinine ratio; CKD ¼ chronic kidney disease; eGFR ¼ estimated
glomerular ﬁltration rate.
Figure 2 Primary Endpoint: CI-AKI Occurrence
The incidence of the primary endpoint was signiﬁcantly lower in the rosuvastatin
group than in the control group (2.3% vs. 3.9%, p ¼ 0.01).
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66signiﬁcantly lower with rosuvastatin. Furthermore, post-
procedural hsCRP levels were higher in patients with CI-
AKI (1.40 mg/l; interquartile range: 0.60 to 4.90 mg/l vs.
0.40 mg/l; interquartile range: 0.20 to 1.00 mg/l, respec-
tively; p ¼ 0.0054).
Considering all patients, 7 developed both CI-AKI and
worsening heart failure, 85 developed CI-AKI only, and 96
developed worsening heart failure only, whereas 2,810
patients did not develop either of the 2 (McNemar test:
p ¼ 0.226), suggesting that the effects of rosuvastatin on
cardiac function were independent of changes in renal
function. Baseline hemoglobin levels were lower and prev-
alence of anemia was higher in patients who developed CI-
AKI (all: p < 0.05) (Table 6).
There were no signiﬁcant differences between the 2
groups in the rates of muscle pain, liver function tests results,
gastrointestinal disorders, or incidence of edema or rash.
Discussion
This is the ﬁrst large randomized, multicenter, prospec-
tive study to evaluate the safety and efﬁcacy of statin therapy
for the prevention of CI-AKI in DM patients with
mild-to-moderate CKD. In this trial, we observed that
periprocedural administration of rosuvastatin, 10 mg daily
for a short duration (5 days), reduced the incidence ofCI-AKI in patients with type 2 DM and CKD, suggesting
that a short course of oral statin may reduce the incidence of
CI-AKI after contrast medium injection in these patients.
These results are of clinical signiﬁcance because CI-AKI is
a severe complication in patients with already impaired
kidney function.
We also evaluated incremental risk factors in these high-
risk patients for CI-AKI development and observed that
ACS, NYHA functional classiﬁcation, anemia and decreased
eGFR were independent correlates of CI-AKI, consistent
with previous studies (20,21). Because these risk factors can
be easily identiﬁed, prophylactic measures for the prevention
of CI-AKI should be considered in these patients.
A recent study showed that statin was useful in pre-
venting acute kidney injury following cardiovascular
surgery (22). Furthermore, several studies reported that
statins may be effective in preventing CI-AKI (11,23).
However, the present study is the ﬁrst to evaluate the
preventive effect of rosuvastatin, a potent LDL-C-lowering
statin, on the development of CI-AKI in DM patients with
concomitant CKD who have a high CI-AKI risk. Notably,
the sample size of the present study, almost 3,000 DM
patients with mild-to-moderate CKD, afforded the
statistical power to evaluate differences between statin and
no-statin treatment, and to explore the risk factors asso-
ciated with CI-AKI in this population. In current clinical
practice, many patients with cardiovascular disease do not
use statins (24). Our results show that rosuvastatin can
signiﬁcantly reduce the risk of CI-AKI, even in patients
with normal lipid levels. Therefore, the present study
indicated that in addition to hydration, statin should be
given to all patients with DM and mild CKD who are
receiving contrast medium.
The incidence of CI-AKI in the control group (3.9%) was
lower than anticipated from our sample size calculation
Table 3
Clinical 30-Day Follow-Up After
Contrast Medium Administration
Variables
Rosuvastatin Group
(n ¼ 1,498)
Control Group
(n ¼ 1,500) p Value
All-cause deaths 3 (0.2) 5 (0.3) 0.73
Dialysis/hemoﬁltration 0 (0.0) 2 (0.1) 0.50
Worsening heart failure* 39 (2.6) 64 (4.3) 0.02
*Values are n (%). Deﬁned by change of New York Heart Association classiﬁcation (class change 1).
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67(10%), which was based on CI-AKI rates from prior studies.
In our study, patients with stages 4 and 5 CKD were
excluded and a majority (85%) had stage 2 CKD, in contrast
to ﬁndings of previous studies that enrolled patients with
stage 3 to 4 CKD. Furthermore, it was recommended that
patients be well hydrated prior to their procedure, which
could have decreased the rate of CI-AKI. The median
volumes of the contrast medium administered in our study
(120 ml in the rosuvastatin group and 110 ml in controls)
were less than the volumes administered in previous studies
(ranging from 173 to 234 ml) (11,15), which suggested that
lowering contrast volume by any measure could prevent CI-
AKI in patients with mild CKD. Despite a lower incidence
of CI-AKI in the control group, rosuvastatin treatment
showed a 42% relative risk reduction in CI-AKI.
In the subgroup analysis, the beneﬁcial effects of rosu-
vastatin were manifest mainly in patients with stage 2 CKD.
Current clinical practice does not recommend prevention of
CI-AKI in patients with mild CKD. However, even small
increases in serum creatinine can be associated with worse
clinical outcomes, increasing short- and long-term mortality
independently from baseline sCr values (25,26). Subgroup
analysis also showed that rosuvastatin was less effective in
patients with anemia. Patients with lower hemoglobin
may have iron deﬁciency or inadequate receptors to eryth-
ropoietin. The outer medullary region in the kidney isTable 4 Multivariable Analysis for CI-AKI Predictors of CI-AKI
Variable OR 95% CI p Value
Rosuvastatin 0.60 (0.39–0.94) 0.03
Male 1.09 (0.67–1.78) 0.73
Age 0.999 (0.973–1.026) 0.94
BMI 0.98 (0.91–1.05) 0.57
ACS 1.86 (1.17–2.95) 0.01
Prior myocardial infarction 0.89 (0.50–1.58) 0.69
Diabetes history 0.92 (0.71–1.20) 0.55
NYHA functional classiﬁcation 1.61 (1.14–2.29) 0.01
Hemoglobin 0.986 (0.972–0.999) 0.01
eGFR (<60 ml/min/1.73 m2) 1.77 (1.31–2.40) <0.01
Contrast agent dose 1.002 (0.999–1.005) 0.12
Hydration 0.83 (0.53–1.31) 0.43
ACEI/ARB 1.15 (0.63–2.10) 0.65
Beta-blocker 0.94 (0.54–1.61) 0.82
ACS ¼ acute coronary syndrome(s); CI-AKI ¼ contrast-induced acute kidney injury. All other
abbreviations are as shown in Table 1.particularly susceptible to ischemic injury (27), and contrast
medium could increase oxygen afﬁnity of hemoglobin, and
oxygen delivery to the peripheral tissues might be impaired
(28), resulting in CI-AKI. Anemia is common among
patients with kidney disease and results from decreased red
blood cell survival, toxic inhibitors of erythropoiesis, and
deﬁciency in iron and folate (29). Hemoglobin levels were
not available after the procedure. However, our results
showed that baseline hemoglobin levels were lower in
patients who developed CI-AKI and that the prevalence of
anemia was higher. The JUPITER (Justiﬁcation for the Use
of Statins in Prevention-an Intervention Trial Evaluating
Rosuvastatin) study showed that rosuvastatin increased
hemoglobin levels in patients with anemia and low-grade
inﬂammation (30).
In our study, hydration was performed at the physician’s
discretion, and not all patients received it (only 44.9% of the
rosuvastatin group and 42.8% of the control group) because:
1) 15% of patients had congestive heart failure, and ﬂuid
administration in these patients was restricted; and 2) at an
early stage of the study, clinical guidelines stated that
hydration was not mandatory. With regard to the safety of
rosuvastatin, results of the study were consistent with those
of previous large-scale randomized studies (6,31). Although
there have been reports stating that rosuvastatin increased
proteinuria (32,33), treatment at 10 mg per day for 5 days
had no effect on proteinuria. A recent study showed that
after 104 weeks of treatment with either 80 mg atorvastatin
or 40 mg rosuvastatin daily, the rate of abnormal liver
enzyme levels was lower with rosuvastatin than with ator-
vastatin, and that there was no signiﬁcant difference in the
development of renal impairment (31).
The mechanism of statin in CI-AKI prevention remains
unknown. In the present study, patients who developed CI-
AKI had higher post-procedural hsCRP levels, and the
preventive effect of rosuvastatin on CI-AKI development
was paralleled by a signiﬁcant decrease in post-procedural
hsCRP levels. Inﬂammation may contribute to the patho-
genesis of CI-AKI, and renal protection by rosuvastatin
during exposure to contrast medium could be due to
attenuation of inﬂammatory responses, a phenomenon also
observed in the JUPITER trial (34). Direct toxic effects of
contrast medium on renal cells are also thought to contribute
to the pathogenesis of CI-AKI. A study showed that pre-
treatment with statin prevented epithelial tubular renal cell
apoptosis and increased survival signaling pathways (8).
Preventing contrast medium-induced renal cell apoptosis
seems to play an important role in statins’ effects on CI-AKI
occurrence.
We observed that rosuvastatin signiﬁcantly decreased the
incidence of worsening of heart failure, which might be
based mainly on the following potential mechanisms (35): 1)
attenuation of negative inotropic effects and apoptosis in
myocardial cells by reducing inﬂammatory cytokines; 2)
improvement of endothelial function by increasing the
production of endothelial nitric oxide; 3) reduction of the
Figure 3 Effects of Rosuvastatin on CI-AKI According to Subgroups
These subgroups are provided as a reference only. xn ¼ number of patients with CI-AKI; N ¼ total number of patients in each subgroup. *There were no interaction effects
between rosuvastatin and hydration therapy (p ¼ 0.058) for the incidence of CI-AKI. &Data missing at baseline in 72 patients. #Data missing at baseline in 188 patients.
Missing data were due to unprescribed tests at recruitment. CI ¼ conﬁdence interval; eGFR ¼ estimated glomerular ﬁltration rate; NYHA ¼ New York Heart Association.
Han et al. JACC Vol. 63, No. 1, 2014
Statins to Prevent Contrast-Induced Kidney Injury January 7/14, 2014:62–70
68formation of oxygen-derived free radicals; and 4) decreased
sympathetic nerve activity in patients with heart failure.
However, the exact mechanism by which short-term rosu-
vastatin treatment decreases the incidence of worsening of
heart failure deserves further study.
Indeed, statins are known to exert pleiotropic effects and
to decrease systemic inﬂammation (36), reﬂected by
decreased hsCRP levels (37). Since inﬂammation is a path-
ogenic factor of kidney injury (38), decreasing systemic
inﬂammation and hsCRP levels might be part of the
mechanism explaining the reduced CI-AKI incidence after
rosuvastatin. Because hsCRP is involved in inﬂammation-
mediated decreased endothelial function and vascular
injury (35), hsCRP-mediated inﬂammation might be the
link between worsening heart failure and CI-AKI.
Furthermore, CRP correlates negatively with eGFR (39),
although it is not a unanimous ﬁnding (40). In agreement
with this possible mechanism, our results showed that short-
course rosuvastatin decreased hsCRP levels, decreased CI-
AKI incidence, and decreased worsening of heart failure.Table 5
Occurrence of CI-AKI in Statin-Naive and
Non-Naive Patients
Statin History
Rosuvastatin Group
Naive/Non-Naive (%)
Control Group
Naive/Non-Naive (%) p Value
Statin non-naive 16/628 (2.5%) 27/619 (4.4%) 0.089
Statin-naive 18/870 (2.1%) 31/881 (3.5%) 0.081
All patients 34/1498 (2.3%) 58/1500 (3.9%) 0.01
CI-AKI ¼ contrast-induced acute kidney injury.However, further studies are required to assess the exact
mechanisms.
Study limitations. First, the open-label design of the study
may have introduced bias.However, all events and biomarkers
were collected and adjudicated by a blinded, independent
committee. Second, the ﬁnding that the beneﬁcial effects of
rosuvastatin were not seen in patients with stage 3 CKD was
from a subgroup analysis, and a stratiﬁed prospective study
will be needed in the future. Third, study outcomes may have
been affected by the dose of rosuvastatin, which was relatively
low (10 mg/day), and mean body mass indexes (BMI) in
current Asian population are lower than those in Caucasian
populations with type 2 DM and renal disease. Therefore,
further studies are needed to explore whether the dosage of
rosuvastatin demonstrating beneﬁt is the same for other
populations. However, in an analysis of the Michigan
Cardiovascular Consortium database, the beneﬁts of statins
against CI-AKI in a Caucasian population with a BMI >25
kg/m2 have been well observed (10). Thus, results from that
previous study and from the present study strongly suggestTable 6
Hemoglobin Levels and Anemia Prevalence in
CI-AKI and Non-CI-AKI Patients
Baseline
CI-AKI Patients
(n ¼ 88)
Non-CI-AKI
Patients
(n ¼ 2,837) p Value
Baseline hemoglobin (g/l) 129.9  18.0 135.2  15.8 0.002
Anemia 13 (14.8) 231 (8.1) 0.047
CI-AKI ¼ contrast-induced acute kidney injury.
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69that statins can reduce CI-AKI in Western and Chinese
populations, regardless of BMI. Regarding the dose, 10mg of
rosuvastatin was lower than that usually used in Western
countries. However, given the fact that plasma exposure to the
same dose of rosuvastatin has been observed to be approxi-
mately 2-fold higher in Asian populations than in Caucasians
(41), the relatively low dosage regimen in the present study
might be aligned with the efﬁcacy of higher dosage used in
Western countries. In the TREAT (Trial to Reduce
Cardiovascular Events with Aranesp Therapy) study, 41.5%
of patients with DM and CKD conducted at 623 sites in 24
countries were not taking statins at baseline (42), and statin-
naive patients may be more prevalent in developing countries,
but there is a lack of epidemiological data on this aspect. Of
important value, our results provide strong indications that
patients with DM and CKD should receive short-term
rosuvastatin to prevent CI-AKI, regardless of whether they
previously used statins or not. Finally, subgroup analyses
provided in Figure 3 are only indicative and cannot be used to
make any conclusions. Indeed, the present study was not
powered to detect differences among these small groups.
Conclusions
Rosuvastatin at 10 mg per day for 5 days reduces the inci-
dence of CI-AKI in patients with type 2 DM and CKD,
who were not already on a statin regimen. A short course of
oral statin may reduce the incidence of CIN.
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